Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Celldex Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Celldex Therapeutics, Inc.’s stock price such as:

• Celldex Therapeutics, Inc.’s current stock price and volume
• Why Celldex Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for CLDX from analysts
• CLDX’s stock price momentum as measured by its relative strength

About Celldex Therapeutics, Inc. (CLDX)

Before we jump into Celldex Therapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company’s drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its clinical development programs are Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. The company is headquartered in Hampton, New Jersey.

Want to learn more about Celldex Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Celldex Therapeutics, Inc..

Celldex Therapeutics, Inc.’s Stock Price as of Market Close

As of February 26, 2026, 2:01 PM, CST, Celldex Therapeutics, Inc.’s stock price was $30.320.

Celldex Therapeutics, Inc. is down 1.62% from its previous closing price of $30.820.

During the last market session, Celldex Therapeutics, Inc.’s stock traded between $29.835 and $31.310. Currently, there are approximately 66.42 million shares outstanding for Celldex Therapeutics, Inc..

Celldex Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Celldex Therapeutics, Inc. Stock Price History

Celldex Therapeutics, Inc.’s (CLDX) price is currently up 23.25% so far this month.

During the month of February, Celldex Therapeutics, Inc.’s stock price has reached a high of $31.310 and a low of $22.330.

Over the last year, Celldex Therapeutics, Inc. has hit prices as high as $31.000 and as low as $14.400. Year to date, Celldex Therapeutics, Inc.’s stock is up 11.63%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Celldex Therapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of February 25, 2026, there was 1 analyst who downgraded Celldex Therapeutics, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Celldex Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Celldex Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Celldex Therapeutics, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Celldex Therapeutics, Inc. (CLDX) by visiting AAII Stock Evaluator.

Relative Price Strength of Celldex Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of February 25, 2026, Celldex Therapeutics, Inc. has a weighted four-quarter relative price strength of 7.83%, which translates to a Momentum Score of 71 and is considered to be Strong.

Want to learn more about how Celldex Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Celldex Therapeutics, Inc. Stock Price: Bottom Line

As of February 26, 2026, Celldex Therapeutics, Inc.’s stock price is $30.320, which is down 1.62% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Celldex Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.